 Midhat Farooqi
Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| High-Throughput Nucleotide Sequencing | 8 | 2022 | 99 | 2.030 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 231 | 1.290 |
Why?
| | Sequence Analysis, DNA | 2 | 2021 | 115 | 1.250 |
Why?
| | Brain Neoplasms | 3 | 2023 | 45 | 1.240 |
Why?
| | Glioma | 2 | 2023 | 28 | 1.070 |
Why?
| | Laboratories | 3 | 2022 | 14 | 1.000 |
Why?
| | Chromosomes | 2 | 2021 | 3 | 0.930 |
Why?
| | Genome, Human | 2 | 2022 | 86 | 0.930 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 6 | 0.880 |
Why?
| | Humans | 27 | 2024 | 6896 | 0.870 |
Why?
| | Genetic Testing | 2 | 2020 | 87 | 0.800 |
Why?
| | Molecular Sequence Annotation | 1 | 2021 | 9 | 0.760 |
Why?
| | Hepacivirus | 2 | 2017 | 2 | 0.760 |
Why?
| | Hepatitis C | 2 | 2017 | 4 | 0.760 |
Why?
| | Medical History Taking | 1 | 2020 | 4 | 0.720 |
Why?
| | Mutation | 7 | 2023 | 212 | 0.710 |
Why?
| | Syndactyly | 1 | 2019 | 4 | 0.700 |
Why?
| | Skin Abnormalities | 1 | 2019 | 3 | 0.700 |
Why?
| | Craniofacial Abnormalities | 1 | 2019 | 10 | 0.700 |
Why?
| | Medulloblastoma | 1 | 2019 | 10 | 0.700 |
Why?
| | Autism Spectrum Disorder | 1 | 2020 | 32 | 0.690 |
Why?
| | Intestines | 1 | 2019 | 29 | 0.680 |
Why?
| | Organ Transplantation | 1 | 2017 | 6 | 0.610 |
Why?
| | Tissue and Organ Procurement | 1 | 2017 | 17 | 0.610 |
Why?
| | Tissue Donors | 1 | 2017 | 30 | 0.610 |
Why?
| | Antiviral Agents | 1 | 2017 | 30 | 0.600 |
Why?
| | Oligonucleotide Probes | 1 | 2016 | 4 | 0.550 |
Why?
| | Disease | 1 | 2016 | 7 | 0.550 |
Why?
| | Clinical Chemistry Tests | 1 | 2015 | 1 | 0.520 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 3 | 0.520 |
Why?
| | Hyponatremia | 1 | 2015 | 2 | 0.520 |
Why?
| | Glutamate Decarboxylase | 1 | 2014 | 2 | 0.480 |
Why?
| | Plasma Exchange | 1 | 2014 | 2 | 0.480 |
Why?
| | Autoantibodies | 1 | 2014 | 11 | 0.480 |
Why?
| | Epilepsy | 1 | 2014 | 14 | 0.470 |
Why?
| | Female | 10 | 2021 | 3525 | 0.460 |
Why?
| | Child | 9 | 2023 | 3364 | 0.430 |
Why?
| | Male | 8 | 2020 | 3337 | 0.400 |
Why?
| | Young Adult | 6 | 2023 | 647 | 0.390 |
Why?
| | Adult | 6 | 2023 | 1181 | 0.350 |
Why?
| | Infant | 7 | 2023 | 1446 | 0.320 |
Why?
| | Retrospective Studies | 4 | 2023 | 1296 | 0.300 |
Why?
| | Data Accuracy | 2 | 2021 | 6 | 0.240 |
Why?
| | Polypyrimidine Tract-Binding Protein | 1 | 2024 | 2 | 0.230 |
Why?
| | Prognosis | 3 | 2021 | 211 | 0.230 |
Why?
| | Glioblastoma | 1 | 2023 | 17 | 0.220 |
Why?
| | World Health Organization | 1 | 2023 | 8 | 0.220 |
Why?
| | Ameloblastoma | 1 | 2023 | 2 | 0.220 |
Why?
| | Odontogenic Tumors | 1 | 2023 | 2 | 0.220 |
Why?
| | Cholesterol | 2 | 2015 | 9 | 0.220 |
Why?
| | Myofibromatosis | 1 | 2022 | 1 | 0.210 |
Why?
| | Infant, Newborn | 3 | 2020 | 816 | 0.210 |
Why?
| | Animals | 5 | 2024 | 729 | 0.200 |
Why?
| | Prenatal Diagnosis | 1 | 2021 | 14 | 0.200 |
Why?
| | Neurons | 2 | 2014 | 19 | 0.200 |
Why?
| | Neoplasms | 1 | 2024 | 128 | 0.190 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2021 | 3 | 0.190 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2021 | 4 | 0.190 |
Why?
| | Rhabdomyosarcoma | 1 | 2021 | 6 | 0.190 |
Why?
| | Polycythemia Vera | 1 | 2021 | 2 | 0.190 |
Why?
| | Viral Load | 2 | 2017 | 14 | 0.190 |
Why?
| | RNA, Viral | 2 | 2017 | 13 | 0.190 |
Why?
| | Reference Values | 1 | 2021 | 39 | 0.190 |
Why?
| | Tissue Array Analysis | 1 | 2020 | 5 | 0.190 |
Why?
| | Follow-Up Studies | 2 | 2020 | 304 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 31 | 0.170 |
Why?
| | Leiomyosarcoma | 1 | 2019 | 1 | 0.170 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2019 | 1 | 0.170 |
Why?
| | Fibroma, Desmoplastic | 1 | 2019 | 1 | 0.170 |
Why?
| | Skull Base Neoplasms | 1 | 2019 | 2 | 0.170 |
Why?
| | Thalassemia | 1 | 2019 | 2 | 0.170 |
Why?
| | Sequence Deletion | 1 | 2019 | 12 | 0.170 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 10 | 0.170 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 21 | 0.170 |
Why?
| | Cell Nucleus Shape | 1 | 2019 | 1 | 0.170 |
Why?
| | Ikaros Transcription Factor | 1 | 2019 | 3 | 0.170 |
Why?
| | Myelodysplastic Syndromes | 1 | 2019 | 11 | 0.170 |
Why?
| | Tumor Suppressor Proteins | 1 | 2019 | 15 | 0.170 |
Why?
| | Genetic Diseases, Inborn | 1 | 2019 | 20 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 66 | 0.170 |
Why?
| | Gene Deletion | 1 | 2019 | 13 | 0.170 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 52 | 0.170 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 7 | 0.170 |
Why?
| | Middle Aged | 2 | 2017 | 608 | 0.170 |
Why?
| | Rats | 3 | 2014 | 106 | 0.160 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 7 | 0.160 |
Why?
| | Immunohistochemistry | 2 | 2019 | 48 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 348 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 50 | 0.160 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 1 | 0.160 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2018 | 1 | 0.160 |
Why?
| | Genes, T-Cell Receptor gamma | 1 | 2018 | 1 | 0.160 |
Why?
| | Child, Preschool | 5 | 2021 | 1569 | 0.160 |
Why?
| | Skin Neoplasms | 1 | 2018 | 11 | 0.160 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 65 | 0.150 |
Why?
| | Kidney | 1 | 2017 | 94 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2022 | 54 | 0.140 |
Why?
| | Laboratory Proficiency Testing | 1 | 2016 | 2 | 0.140 |
Why?
| | Genotype | 1 | 2017 | 410 | 0.140 |
Why?
| | Kidney Transplantation | 1 | 2017 | 115 | 0.140 |
Why?
| | Computational Biology | 1 | 2016 | 43 | 0.130 |
Why?
| | Artifacts | 1 | 2015 | 7 | 0.130 |
Why?
| | HeLa Cells | 1 | 2014 | 17 | 0.120 |
Why?
| | Cells, Cultured | 1 | 2014 | 84 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 31 | 0.120 |
Why?
| | Carcinogenesis | 2 | 2024 | 9 | 0.110 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 1 | 0.110 |
Why?
| | Lipogenesis | 1 | 2012 | 1 | 0.110 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2012 | 1 | 0.110 |
Why?
| | Insulin | 1 | 2012 | 50 | 0.100 |
Why?
| | Liver | 1 | 2012 | 126 | 0.100 |
Why?
| | Hair Diseases | 1 | 2010 | 1 | 0.090 |
Why?
| | Anticholesteremic Agents | 1 | 2010 | 2 | 0.090 |
Why?
| | Simvastatin | 1 | 2010 | 10 | 0.090 |
Why?
| | Alleles | 2 | 2022 | 214 | 0.090 |
Why?
| | Adolescent | 3 | 2021 | 2197 | 0.090 |
Why?
| | Survival Rate | 2 | 2020 | 83 | 0.090 |
Why?
| | Diagnosis, Differential | 2 | 2019 | 77 | 0.080 |
Why?
| | Isoxazoles | 1 | 2008 | 1 | 0.080 |
Why?
| | Small Molecule Libraries | 1 | 2008 | 5 | 0.080 |
Why?
| | Stem Cells | 1 | 2008 | 29 | 0.080 |
Why?
| | Pilot Projects | 2 | 2020 | 120 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2008 | 59 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2020 | 41 | 0.070 |
Why?
| | RNA Splicing | 1 | 2024 | 14 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 59 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 7 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2023 | 18 | 0.060 |
Why?
| | Formaldehyde | 1 | 2023 | 4 | 0.060 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2023 | 3 | 0.060 |
Why?
| | Genetic Heterogeneity | 1 | 2023 | 5 | 0.050 |
Why?
| | Imatinib Mesylate | 1 | 2022 | 1 | 0.050 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2022 | 2 | 0.050 |
Why?
| | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2022 | 3 | 0.050 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2022 | 4 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2022 | 13 | 0.050 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 18 | 0.050 |
Why?
| | Exome | 1 | 2022 | 36 | 0.050 |
Why?
| | Microarray Analysis | 1 | 2021 | 6 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2021 | 12 | 0.050 |
Why?
| | MyoD Protein | 1 | 2021 | 4 | 0.050 |
Why?
| | Polycythemia | 1 | 2021 | 1 | 0.050 |
Why?
| | Janus Kinase 2 | 1 | 2021 | 8 | 0.050 |
Why?
| | Exons | 1 | 2021 | 34 | 0.050 |
Why?
| | Pregnancy | 1 | 2021 | 216 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2020 | 37 | 0.050 |
Why?
| | Mitoxantrone | 1 | 2020 | 4 | 0.040 |
Why?
| | Vincristine | 1 | 2020 | 6 | 0.040 |
Why?
| | Bortezomib | 1 | 2020 | 8 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 150 | 0.040 |
Why?
| | Salvage Therapy | 1 | 2020 | 6 | 0.040 |
Why?
| | Doxorubicin | 1 | 2020 | 15 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2020 | 9 | 0.040 |
Why?
| | Asparaginase | 1 | 2020 | 13 | 0.040 |
Why?
| | Algorithms | 1 | 2020 | 105 | 0.040 |
Why?
| | Dexamethasone | 1 | 2020 | 29 | 0.040 |
Why?
| | Chromogranins | 1 | 2019 | 2 | 0.040 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2019 | 2 | 0.040 |
Why?
| | Neonatal Screening | 1 | 2019 | 7 | 0.040 |
Why?
| | beta Catenin | 1 | 2019 | 9 | 0.040 |
Why?
| | Multigene Family | 1 | 2019 | 8 | 0.040 |
Why?
| | Cohort Studies | 1 | 2020 | 289 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 7 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 42 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 34 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 45 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 3 | 0.040 |
Why?
| | Comparative Genomic Hybridization | 1 | 2019 | 9 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 4 | 0.040 |
Why?
| | Age Factors | 1 | 2019 | 210 | 0.040 |
Why?
| | Clone Cells | 1 | 2018 | 2 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2018 | 32 | 0.040 |
Why?
| | Biopsy | 1 | 2018 | 60 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 99 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2018 | 84 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2018 | 199 | 0.040 |
Why?
| | Phenotype | 1 | 2018 | 257 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2016 | 33 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2012 | 1 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2012 | 1 | 0.030 |
Why?
| | Glucagon | 1 | 2012 | 3 | 0.030 |
Why?
| | Rats, Transgenic | 1 | 2012 | 3 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 5 | 0.030 |
Why?
| | Multiprotein Complexes | 1 | 2012 | 4 | 0.030 |
Why?
| | Immunoblotting | 1 | 2012 | 11 | 0.030 |
Why?
| | DNA Primers | 1 | 2012 | 30 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 50 | 0.030 |
Why?
| | Proteins | 1 | 2012 | 27 | 0.030 |
Why?
| | Epidermis | 1 | 2010 | 1 | 0.020 |
Why?
| | Hair Follicle | 1 | 2010 | 1 | 0.020 |
Why?
| | Body Size | 1 | 2010 | 7 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2010 | 59 | 0.020 |
Why?
| | Mice | 1 | 2010 | 348 | 0.020 |
Why?
| | Receptors, AMPA | 1 | 2008 | 1 | 0.020 |
Why?
| | Molecular Structure | 1 | 2008 | 4 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2008 | 7 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2008 | 4 | 0.020 |
Why?
| | Phosphorylation | 1 | 2008 | 22 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 14 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2008 | 26 | 0.020 |
Why?
| | Cell Line | 1 | 2008 | 81 | 0.020 |
Why?
| | Gene Expression | 1 | 2008 | 67 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 94 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2008 | 68 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|